Samit Ganguly

Jul 15, 2024 | ascpt.onlinelibrary.wiley.com | Mohamed Kamal |Samit Ganguly |Ananth Kadambi |Patrick Smith

CONFLICTS OF INTEREST The authors declared no competing interests for this work. 1Shaw, D.L., Dhruva, S.S. & Ross, J.S. Coverage of novel therapeutic agents by medicare prescription drug plans following FDA approval. J. Manag. Care Spec. Pharm. 24, 1230–1238 (2018). 2Hill-McManus, D., Marshall, S., Liu, J., Willke, R.J. & Hughes, D.A. Linked pharmacometric-pharmacoeconomic modeling and simulation in clinical drug development. Clin. Pharmacol. Ther. 110, 49–63 (2021). 3Kamal, M.A. et al.

Dec 13, 2023 | ascpt.onlinelibrary.wiley.com | John Davis |Samit Ganguly |Marçal Bravo Padros |Daniela J. Conrado

Subcutaneous (SC) administration of monoclonal antibodies (mAbs) can reduce treatment burden for patients and healthcare systems compared to intravenous (IV) infusion through shorter administration times, made possible by convenient, patient-centric devices. A deeper understanding of clinical pharmacology principles related to efficacy and safety of SC-administered mAbs over the past decade has streamlined SC product development.